Help Your Recent MI Patients Achieve Lower LDL-C and Reduce the Risk of Another MI
Repatha® is indicated:
- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL C
Important Safety Information
- Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
- Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
- Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.
From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
- Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).
Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha®compared with 7.7% in patients that received placebo.
- Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.
Please see full Prescribing Information.
RICHARD MULLVAIN, RPh
A clinical pharmacist, Richard Mullvain’s research interests include cardiovascular risk reduction, anticoagulation, and heart attack care. He is the co-author of articles published in Critical Pathways in Cardiology and Circulation: Cardiovascular Quality and Outcomes.
Richard Mullvain, RPh will provide community pharmacists with key information about Repatha® (evolocumab) allowing the pharmacist to provide patient education along their treatment journey in this webcast, “Help Your Recent MI Patients Achieve Lower LDL-C And Reduce The Risk Of Another MI.”
- Appreciate the importance of LDL-C reduction in patients with very high-risk atherosclerotic cardiovascular disease and current guideline recommendations for the addition of a PCSK9i monoclonal antibody, like Repatha®, to statin therapy
- Take a closer look at Repatha®, highlighting its mechanism of action and its established efficacy and safety data
- Review Repatha® product information, dosing options, and available resources for administration training
- Explore the access and affordability of Repatha®, features of the Repatha® Copay Card for commercially insured patients, and RepathaReady® patient support services and resources